loading page

Efficacy of Bisphosphonates and Recombinant Parathyroid Hormone in Treatment of Osteoporosis in Pakistan
  • +4
  • Rabia Zahid,
  • Sadia Zahid,
  • Ridda Sajjad,
  • Urooj Naseer,
  • Muhammad Qayyum,
  • Izhar Ullah,
  • Ejaz Rafique
Rabia Zahid
Government College University Faisalabad
Author Profile
Sadia Zahid
University of the Poonch Rawalakot
Author Profile
Ridda Sajjad
University of the Poonch Rawalakot
Author Profile
Urooj Naseer
University of the Poonch Rawalakot
Author Profile
Muhammad Qayyum
University of the Poonch Rawalakot
Author Profile
Izhar Ullah
University of the Poonch Rawalakot
Author Profile
Ejaz Rafique
The University of Lahore
Author Profile

Abstract

Background; Osteoporosis is one of such disease which causes bone mass reduction by decreased formation of new bones. Low bone mineral density is frequent factor for osteoporosis. Increased osteoclast life span and advanced osteocytes as well as osteoblasts apoptosis is well adopted pathophysiological mechanism for low bone mass. Women are more prone than man. Approximately 200 million women have osteoporosis worldwide. Objective; Therefore, this study is designed to compare efficacy of bisphosphonates and recombinant human Para-thyroid hormone in treatment of osteoporosis. Main outcome measures; The comparison of these two treatment strategies is based upon therapeutic effectiveness, cost of therapy and availability of the drugs. Methods; The total duration of study was 1 year and during the study period a total 60 samples were analyzed randomly. Data was collected using a well-designed questionnaire. Results; rhPTH increase bone mass density (BMD) by 8-9% while bisphosphonates and estrogen therapy increase BMD 3-5% during the same time period. Conclusion; The current study was conducted in local population so that we could offer them the test possible treatment among the two most common treatment therapies available for osteoporosis.